Arlene Chapman

Renowned for innovative teaching in nephrology, Dr. Arlene Chapman is a distinguished Professor of Medicine and Chief of the Section of Nephrology at the University of Chicago Medicine. With a career dedicated to advancing the understanding and treatment of kidney diseases, Dr. Chapman has become a leading figure in the study of autosomal dominant polycystic kidney disease (ADPKD). Her research is particularly focused on the development and application of novel imaging biomarkers, which are crucial for assessing disease progression and evaluating the efficacy of new treatments. Dr. Chapman's clinical expertise extends beyond ADPKD to encompass a wide range of hereditary renal diseases. Her interests include autosomal recessive kidney diseases, congenital anomalies of the kidney and urinary tract (CAKUT) disorders, ciliopathies, tuberous sclerosis complex, and von Hippel Lindau disease. This broad spectrum of interests underscores her commitment to improving patient outcomes across various genetic kidney conditions. Over the past two decades, Dr. Chapman has consistently secured funding from the National Institutes of Health (NIH), a testament to the significance and impact of her research. Her work not only contributes to the scientific community but also directly influences clinical practices, offering new hope and strategies for patients with hereditary kidney diseases. In addition to her research and clinical work, Dr. Chapman is deeply involved in mentoring the next generation of nephrologists and researchers. Her dedication to education is evident in her innovative teaching methods, which inspire students and trainees to pursue excellence in both clinical practice and research. Dr. Chapman's contributions to nephrology have been recognized through numerous awards and honors, reflecting her status as a leader in the field. Her ongoing commitment to advancing the understanding of kidney diseases continues to drive her research and clinical endeavors, making a lasting impact on the lives of patients and the broader medical community.